Method for the determination of the concentration of asymmetric dimethylarginine
Elevated plasma levels of ADMA are described for a number of diseases as hypertension, hypercholesterolemia, renal insufficiency or diabetes mellitus. The invention provides a method for the simultaneous determination of the concentration of asymmetric dimethylarginine (ADMA), arginine and symmetric dimethylarginine (SDMA) in biological probes using chromatography combined with tandem mass spectrometry.
Further Information: PDF
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Phone: +49 (0)391/8 10 72 20
Contact
Dr. Stefan Schünemann
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…